After a brief delay, the TrumpRx pharmaceutical platform is scheduled to launch at 7 pm EST on Thursday. The new government initiative will allow patients to pay cash for discounted drugs from major pharmaceutical companies such as Eli Lilly, Pfizer, Novo Nordisk, and Amgen.
President Donald Trump will make an announcement about the launch alongside Mehmet Oz, chief of the Centers for Medicare and Medicaid Services (CMS). Joe Gebbia, cofounder of Airbnb and member of the Department of Government Efficiency (DOGE), will also be present at the event. Axios first reported these details.
“This historic announcement will impact millions of Americans. You won’t want to miss it! Tune in,” White House press secretary Karoline Leavitt said in a statement to Axios.
The Trump administration had previously delayed the launch last week due to unspecified reasons, possibly related to concerns about anti-kickback regulations. Health Secretary Robert F. Kennedy Jr. had stated that the launch would likely take place “probably in the next 10 days,” according to Politico at that time.
Initial drugs available through TrumpRx will include Amgen’s Repatha for lowering cholesterol, Pfizer’s Airsupra for asthma, and GLP-1 products from Novo Nordisk and Eli Lilly.
President Trump has emphasized that his goal is to lower drug prices for patients. However, some experts question whether direct-to-consumer models like this can deliver broad savings on pharmaceuticals. Jason Shafrin, senior managing director at FTI Consulting’s Center for Healthcare Economics & Policy, told BioSpace in November: “Only the uninsured or those with high-deductible plans might experience net savings through DTC purchases, while the majority of insured patients would pay less through traditional insurance channels.”
Tyler Young, an independent pharmacist and owner of Vashon Pharmacy, also commented by email that month: DTC pricing might help “a select group of cash-paying patients” seeking certain drugs, particularly GLP-1s.
